Interactions between DNA and a Pyrene-Labeled Surfactant Probed by Pyrene Excimer Formation, Transmission Electron Microscopy, and Dynamic Light Scattering.

Langmuir

Institute for Polymer Research, Waterloo Institute for Nanotechnology, Department of Chemistry, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada.

Published: February 2025

The interactions between calf thymus DNA and a pyrene-labeled gemini surfactant termed PyO-3-12 were investigated by using dynamic light scattering (DLS), transmission electron microscopy (TEM), and pyrene excimer formation (PEF) between an excited and a ground-state pyrene. PyO-3-12 was prepared with two dimethylammonium bromide headgroups linked with a propyl spacer, with one ammonium bearing a dodecyl tail and the other bearing a 1-pyrenemethoxyhexyl pendent. The size and electrostatic properties of the colloidal species were characterized by DLS, and TEM was used to describe the overall dimensions and morphologies of the aggregates. PEF enabled the study of PyO-3-12 at the molecular level. The association of PyO-3-12 and DNA was studied in detail for two specific PyO-3-12 concentrations of 16 and 56 μM using a (∓) ratio equal to the [DNA]/[PyO-3-12] ratio with [DNA] expressed in terms of DNA base pairs, yielding a (∓) ratio ranging from 0.1 to 10. An increase in PyO-3-12 association upon adding DNA was detected through an increase in PEF. Analysis of the fluorescence decays indicated a progressive binding of PyO-3-12 to DNA until the equicharge point was reached after which all PyO-3-12 surfactants were bound to DNA. The formation of large colloidal aggregates was observed by DLS, which showed a spike in the hydrodynamic diameter () as the (∓) ratio approached unity. Analysis of the fluorescence spectra suggested that the excited pyrenyl labels experienced a more hydrophobic environment for the lipoplexes generated by the 56 μM PyO-3-12 solutions, which appeared smaller and more globular in the TEM images than the lipoplexes obtained with the lower 16 μM PyO-3-12 concentration. Together, these experiments suggest that the concentrations of the cationic gemini surfactants and DNA are important parameters for the morphology of lipoplexes with possible implications for their transfection efficiency.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.langmuir.4c03449DOI Listing

Publication Analysis

Top Keywords

∓ ratio
12
pyo-3-12
10
dna pyrene-labeled
8
pyrene excimer
8
excimer formation
8
transmission electron
8
electron microscopy
8
dynamic light
8
light scattering
8
pyo-3-12 dna
8

Similar Publications

Association Between Uric Acid to High-Density Lipoprotein Cholesterol Ratio and Abdominal Aortic Aneurysm: A Single-Center Retrospective Study.

J Inflamm Res

March 2025

The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, People's Republic of China.

Objective: Uric acid (UA) to high-density lipoprotein cholesterol (HDL-C) ratio (UHR) has been recognized as a novel biomarker for evaluating inflammatory and anti-inflammatory interaction. However, it is not known whether UHR is related to abdominal aortic aneurysm (AAA). The current research aims to explore the potential role of UHR in predicting AAA.

View Article and Find Full Text PDF

Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial).

Dig Liver Dis

March 2025

Service de Pharmacologie Médicale, CHU de Tours, Tours, France; UMR 1327, ISCHEMIA, Membrane signalling and inflammation in reperfusion injuries, INSERM, Université de Tours, Tours, France; Plateforme Recherche, Centre Pilote de suivi Biologique des traitements par Anticorps, CHU de Tours, Tours, France.

Bevacizumab shows inter-individual pharmacokinetic variability, with an exposure-response relationship in metastatic colorectal cancer (mCRC) patients. This study explores whether a double dose of bevacizumab, compared to a standard dose, increases efficacy in mCRC patients treated with bevacizumab-based chemotherapy as first-line therapy and who have a low initial trough concentration of bevacizumab. PHARBEVACOL is a multicenter, randomized, double-blind, two-parallel group trial.

View Article and Find Full Text PDF

Background: We aim to report on somatostatin receptor (SSTR)-targeted molecular imaging and therapy in patients with advanced esthesioneuroblastoma (ENB).

Patients And Methods: Five patients with ENB [Kadish stage D in 5/5 (100%); Hyams grade 2 in 2/5 (40%), grade 3 in 2/5 (40%), undetermined in 1/5 (20%)] underwent SSTR-directed PET/CT. We quantified SSTR-avid tumor volume (TV), maximum SUV (SUVmax), and target-to-background ratios (TBR).

View Article and Find Full Text PDF

Objective: To analyze the effectiveness of prophylactic mesh augmentation (PMA) of the abdominal wall following open aortic aneurysm repair as compared to primary sutured closure in preventing incisional hernia (IH) formation by performing an individual patient-data meta-analysis (IPDMA).

Summary Background Data: IH is a prevalent complication after abdominal surgery, especially in high-risk groups. PMA of the abdominal wall has been studied as a preventive measure for IH-formation, but strong recommendations are lacking.

View Article and Find Full Text PDF

Introduction: Androgen-receptor pathway inhibitors such as abiraterone and enzalutamide have demonstrated clinical benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to conduct a meta-analysis of published real-world evidence studies comparing outcomes among patients treated with enzalutamide or abiraterone in the first-line setting.

Methods: We conducted a systematic literature review to identify eligible studies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!